2022
DOI: 10.1016/j.ijscr.2022.106859
|View full text |Cite
|
Sign up to set email alerts
|

Mixed mucinous cystadenoma with benign Brenner tumor in a huge ovarian mass, a case report and review of literature

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
2
0
2

Year Published

2024
2024
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(5 citation statements)
references
References 9 publications
1
2
0
2
Order By: Relevance
“…It was also reported that about 20% of BTs could be accompanied by mucinous cystadenoma, serous cystadenoma, benign cystic teratoma, or struma ovarii (20). Similarly, in our study, seven patients (28%) had concomitant benign ovarian tumors: four cases were BBT combined with serous cystadenoma, seromucinous tumor, ovarian fibroma, and endometrioid cyst, respectively, and the other three were associated with mucinous cystadenoma, which was similar to what Roma and Masand reported (21,22). Some scholars believe that the reason why mucinous cystadenoma and BBT can coexist is that they have a common clonal origin (23,24).…”
Section: Discussionsupporting
confidence: 90%
“…It was also reported that about 20% of BTs could be accompanied by mucinous cystadenoma, serous cystadenoma, benign cystic teratoma, or struma ovarii (20). Similarly, in our study, seven patients (28%) had concomitant benign ovarian tumors: four cases were BBT combined with serous cystadenoma, seromucinous tumor, ovarian fibroma, and endometrioid cyst, respectively, and the other three were associated with mucinous cystadenoma, which was similar to what Roma and Masand reported (21,22). Some scholars believe that the reason why mucinous cystadenoma and BBT can coexist is that they have a common clonal origin (23,24).…”
Section: Discussionsupporting
confidence: 90%
“…In term of laterality Right:Left ovary ratio was found 4:3. [4,5,6,7,8,9,10] Our patient was also a post-menopausal woman with history of 5-month progressive abdominal discomfort and distention with huge 18 × 16 × 12 cm left ovarian mass who underwent explorative laprotomy with left adnexal excision and pathological diagnosis of borderline mucinous tumor associated with benign Brenner tumor was made. Ovarian mucinous tumors are divided into benign (mucinous cystadenoma), borderline, and malignant (mucinous carcinoma); majority mucinous tumors are benign or borderline.…”
Section: Discussionmentioning
confidence: 99%
“…[4] This is a case report of a 72-year-old female patient diagnosed with Brenner tumor that was discovered incidentally associated with a giant borderline mucinous tumor of the ovary. [5] Nazari F et al [6] Dougherty D et al [7] Rajshree D.K. et al [8] Pradhan P. et al [9] Anoedward et al [10] Sridevi S. et al [ On routine histological evaluation, final diagnosis stated mucinous cystic tumor of borderline malignancy with areas of benign mucinous cystadenoma along with benign Brenner tumor with transitional cell nests embedded in a dense fibrous stroma.…”
Section: Introductionmentioning
confidence: 99%
“…În 30-36% din cazurile cu TOB, tumorile sincrone sunt detectate în ovarul ipsilateral sau contra-lateral, inclusiv chistadenom mucinos [1,7,12,13,17,18], chistadenom seros [7,13], endometriom [7], strumă ovariană [7], strumă ovariană și chistadenom mucinos [19], teratom ovarian matur [7], leiomiom ovarian [20], limfom [2]. În studiul Montoriol PF.…”
Section: Descrierea Cazului Clinicunclassified
“…Tratamentul de elecție pentru TOB este intervenția chirurgicală, al cărei volum este determinat de caracteristicile preoperatorii și intraoperatorii ale tumorii, de vârsta pacienților și de dorința de a păstra fertilitatea [1,7,15]. În cazul TOB benigne, la pacientele de vârstă reproductivă se efectuează intervenții tumor-/ovar-/anexectomie; în menopauză se efectuează histerectomie totală (HET) cu anexectomie bilaterală (AE) [1,7,12,13,18]. În TOB borderline, volumul intervențiilor chirurgicale la pacientele de vârstă fertilă este justificat de implementarea intervențiilor de conservare a organelor (AE) și a HET în combinație cu AE bilaterală la pacientele în menopauză și postmenopauză [11,13,15].…”
Section: Descrierea Cazului Clinicunclassified